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Abstract
Background: The ABC transporter P-glycoprotein (P-gp) is recognized as a site for drug-drug
interactions and provides a mechanistic explanation for clinically relevant pharmacokinetic
interactions with digoxin. The question of whether several P-gp inhibitors may have additive effects
has not yet been addressed.
Methods: We evaluated the effects on serum concentrations of digoxin (S-digoxin) in 618 patients
undergoing therapeutic drug monitoring. P-gp inhibitors were classified as Class I, with a known
effect on digoxin kinetics, or Class II, showing inhibition in vitro but no documented effect on digoxin
kinetics in humans. Mean S-digoxin values were compared between groups of patients with
different numbers of coadministered P-gp inhibitors by a univariate and a multivariate model,
including the potential covariates age, sex, digoxin dose and total number of prescribed drugs.
Results: A large proportion (47%) of the digoxin patients undergoing therapeutic drug monitoring
had one or more P-gp inhibitor prescribed. In both univariate and multivariate analysis, S-digoxin
increased in a stepwise fashion according to the number of coadministered P-gp inhibitors (all P
values < 0.01 compared with no P-gp inhibitor). In multivariate analysis, S-digoxin levels were 1.26
± 0.04, 1.51 ± 0.05, 1.59 ± 0.08 and 2.00 ± 0.25 nmol/L for zero, one, two and three P-gp inhibitors,
respectively. The results were even more pronounced when we analyzed only Class I P-gp
inhibitors (1.65 ± 0.07 for one and 1.83 ± 0.07 nmol/L for two).
Conclusions: Polypharmacy may lead to multiple drug-drug interactions at the same site, in this
case P-gp. The S-digoxin levels increased in a stepwise fashion with an increasing number of
coadministered P-gp inhibitors in patients taking P-gp inhibitors and digoxin concomitantly. As
coadministration of digoxin and P-gp inhibitors is common, it is important to increase awareness
about P-gp interactions among prescribing clinicians.
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Background
Knowledge about mechanisms of interactions makes it
possible to predict and prevent pharmacokinetic drug
interactions. The MDR1 gene encodes the ABC transporter
P-glycoprotein (P-gp), which functions as an efflux pump
and is recognized as a site for drug-drug interactions [1-5].
Several commonly used drugs inhibit P-gp efflux, which
can increase gastrointestinal absorption, decrease elimi-
nation in the bile and urine, and affect the distribution of
drugs to certain compartments, such as the central nerv-
ous system (CNS) [2-5].
Digoxin has a narrow therapeutic range and is recognized
as a high-affinity P-gp substrate [6]. Risk factors for dig-
oxin toxicity are well known to clinicians and include
advanced age, impaired renal function and low body
weight. Despite this, statistics show that unintended dig-
oxin intoxication remains a common problem [7]. Dig-
oxin has again become a subject of discussion after recent
publications demonstrated sex-based differences in mor-
tality [8] and increased mortality among men with serum
concentrations of digoxin (S-digoxin) > 1.5 nmol/L [9]. In
this context, heightened attention to a patient's S-digoxin
level is warranted.
Certain inhibitors of P-gp have been demonstrated to
increase S-digoxin levels in healthy volunteers [2,10,11],
sometimes in a dose-dependent manner [12]. As digoxin
is frequently coadministered with P-gp inhibitors, we
wanted to i) evaluate whether clinically relevant interac-
tions are observed in a large group of ordinary digoxin
patients and ii) investigate whether patients taking several
P-gp inhibitors have additive elevations in S-digoxin lev-
els compared with patients with one concomitantly pre-
scribed P-gp inhibitor.
Methods
Study population and analysis of S-digoxin
All patients on digoxin therapeutic drug monitoring
(TDM) at Uppsala University hospital (Sweden) over the
past three years were considered for this study. Patients
were included if they were on oral digoxin treatment; their
S-digoxin values were above the detection limit; steady-
state concentrations had been reached; the serum samples
were measured at trough; and information about concom-
itant treatment was available.
The S-digoxin levels had been determined by a fluores-
cence polarization immunoassay (TDx®, Abbott Scandina-
via AB, Sweden).
Substance classification
To classify the concomitantly administered drugs as P-gp
inhibitors, PubMed was systematically searched for the
INN substance name and English spelling combined with
the terms 'P-gp', 'Pgp' and 'MDR1'. Substances were classi-
fied as P-gp inhibitors when demonstrating a clear inhib-
itory effect on P-gp in cellular transport assays, in cellular
uptake assays or in animal models using mdr1a(-/-)mice.
A literature review was also performed combining the
search terms 'digoxin' and the substance names. Any effect
of each drug on digoxin pharmacokinetics in vivo was
documented.
To evaluate whether only P-gp inhibitors with well-recog-
nized digoxin interactions in vivo contribute to a change in
S-digoxin, the P-gp inhibitors were further divided into
two groups: Class I P-gp inhibitors, with well-documented
effects on digoxin pharmacokinetics in vivo, and Class II P-
gp inhibitors, with established P-gp inhibitory effect in
vitro and putative effects on S-digoxin in vivo. Class I and
II P-gp inhibitors were compared with drugs that had no
or unknown effects on P-gp. Only substances adminis-
tered orally were included in the classification.
Statistical analysis
Adjusted mean S-digoxin values for each category of P-gp
were computed on the basis of the regression estimates
calculated with the General Linear Model using Proc GLM
in SAS 8.02 (SAS Institute Inc., NC, USA), with the con-
founding factors at their mean values. Data are presented
as mean values ± SE. Two different models were used: one
univariate and one multivariate, including the potential
covariates age, sex, digoxin dose and total number of pre-
scribed drugs for each individual (all continuous). In
addition, subclass analysis including p-creatinine values
was performed.
Results
Patient characteristics
Therapeutic drug monitoring charts from 618 patients
(256 men and 362 women) fulfilled the inclusion criteria.
The study population included patients with a diagnosis
of heart failure and/or atrial fibrillation. See Table 1 for
patient characteristics. Forty-seven percent of the study
population were taking at least one P-gp inhibitor.
Patients with S-digoxin levels above the recommended
therapeutic range, > 2.5 nmol/L, (the upper limit of the
therapeutic range at the time of the study) were more
likely to have coadministered P-gp inhibitors compared
with patients with S-digoxin = 2.5 nmol/L (68% vs. 47%,
P = 0.01, using Chi-square test).
Substance classification
Our study population had a total of 228 different drug
substances prescribed. Of these, 21 were documented P-
gp inhibitors and eight were P-gp inhibitors with reported
digoxin interactions (Table 2).BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/8
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Association between S-digoxin levels and number of 
coadministered P-gp inhibitors
Overall, patients with concomitant P-gp inhibitors had
higher S-digoxin levels than patients without: 1.55 ± 0.04
compared with 1.26 ± 0.04 nmol/L, P < 0.001 (the results
differed in the third decimal between the univariate and
multivariate analyses [Figure 1A]). Subclass analysis of the
542 patients for whom p-creatinine was available did not
alter these results. An increasing number of P-gp
inhibitors was associated with stepwise elevations in S-
digoxin levels (Figure 1B).
Analysis of classified P-gp inhibitors
The S-digoxin levels were 1.25 ± 0.04 nmol/L for patients
with no P-gp inhibitors compared with 1.65 ± 0.07 and
1.83 ± 0.17 for patients with one and two Class I P-gp
inhibitors, respectively (Figure 2). The differences in the
calculations using the univariate compared with the
multivariate model were minute. The effect on mean S-
Table 1: Patient characteristics
Characteristic TDM patients N = 618
Age (years)* 84 (24–99)
P-creatinine (mmol/L)* 100 (36–598)
Daily digoxin dose (mg)* 0.13 (0.04–0.5)
Concomitant drugs* 5 (1–21)
Patients below therapeutic range (< 1.2 nmol/L) 263
Patients within therapeutic range (1.2–2.5 nmol/L) 317
Patients above therapeutic range (> 2.5 nmol/L) 38
*Median (range). TDM = therapeutic drug monitoring.
Table 2: Drug classification
Class I substance No. of patients using the drug References
Amiodarone 12 [21], [22]                         
Atorvastatin 12 [11], [20]                         
Cyclosporine A 3 [23]                         
Dipyridamole 12 [24]                         
Quinidine 1 [1], [25]                         
Quinine 1 [26], [27]                         
Spironolactone 106 [25]                         
Verapamil 31 [25]                         
Class II substance No. of patients using the drug References
Bromocriptine 1 [28]                         
Flupentixol 1 [29]                         
Glibenclamide 46 [30]                         
Isradipine 2 [21], [31]                         
Lansoprazole 51 [32]                         
Loperamide 2 [33], [34]                         
Medroxyprogesterone 2 [35]                         
Omeprazole 35 [32]                         
Pantoprazole 6 [32]                         
Paroxetine 6 [36]                         
Sertraline 29 [36], [37]                         
Simvastatin 17 [20]                         
Terfenadine 1 [38]                         
The coadministered drugs were classified for their effects on P-gp and on digoxin pharmacokinetics. Class I P-gp inhibitors have well-documented 
effects on digoxin pharmacokinetics in vivo, while Class II P-gp inhibitors have established P-gp inhibitory effects in vitro and putative effects on S-
digoxin in vivo.BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/8
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digoxin levels among patients with Class I P-gp inhibitors
was not solely attributed to the most frequently coadmin-
istered P-gp inhibitors, spironolactone and verapamil,
because exclusion of patients with these drugs gave simi-
lar, although smaller, differences. Patients taking one or
two Class II P-gp inhibitors also tended to have elevated
S-digoxin levels compared with patients with no P-gp
inhibitors, although these differences were not significant
in the multivariate model.
Discussion
Rathore et al. (2003) [9] recently reported that the mortal-
ity rate was increased at S-digoxin levels above 1.5 nmol/
L. Therefore, it is particularly important to be aware of
factors that influence S-digoxin levels. We consider the
magnitudes of the differences seen in S-digoxin in this
study, 20–60% increases, to be of clinical importance. The
patients taking one or more P-gp inhibitor had S-digoxin
levels above 1.5 nmol/L, while patients without P-gp
inhibitors were below this limit.
Pharmacokinetic interactions with digoxin can arise from
mechanisms other than P-gp, for example, changes in
renal function, changes in gut motility or pH, distur-
bances of digoxin-metabolizing intestinal bacteria or pos-
sibly from interactions with other transport proteins, such
as members of the solute carrier family (SLC) [13]. P-gp
seems, however, to be a major determinant for digoxin
pharmacokinetics.
The association between S-digoxin levels and the number of prescribed P-gp inhibitors Figure 1
The association between S-digoxin levels and the number of prescribed P-gp inhibitors (A) Adjusted* S-digoxin 
means for the patients without ('0') (N = 328, S-digoxin mean ± SE 1.26 ± 0.04 nmol/L) or with ('≥ 1'), P-gp inhibitors (N = 290, 
S-digoxin mean ± SE 1.55 ± 0.04 nmol/L). (B) Adjusted* S-digoxin means for patients taking zero, one, two or three P-gp inhib-
itors. The number of patients were 328, 204, 78 and eight, respectively. The S-digoxin means ± SE (nmol/L) were 1.26 ± 0.04, 
1.51 ± 0.05, 1.59 ± 0.08 and 2.00 ± 0.25. *Adjusted for age, sex, digoxin dose and total number of prescribed drugs.
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Drugs with structures similar to digoxin can interfere with
digoxin immunoassays [14]. Of the concomitant drugs
taken by the patients in this study, spironolactone and its
metabolites have been reported to interfere with the dig-
oxin readings [15]. That spironolactone can interfere with
digoxin immunoassays has been known for 30 years [16],
but until recently little information about this effect has
been available for newer digoxin assays. In a 1999 report
by Steimer et al. [17], a case of digoxin toxicity resulted
from falsely low values using the MEIA II assay for digoxin
(AxSYM®; Abbott). Canrenone and spironolactone were
identified as the major interfering substances. In a subse-
quent study, Steimer et al. (2002) [15] examined nine dig-
oxin assays including the TDx® used in our study. False-
negative results were attributable to spironolactone, can-
renone and other steroids in several newer digoxin assays.
In contrast, falsely increased digoxin concentrations could
be detected in the TDx assay®, although these were very
small except in the absence of digoxin and at high concen-
trations of the interfering substance. In updated product
information for the TDx assay® released by Abbott Scandi-
navia AB [18], the results of a careful study of the analyti-
cal interference from spironolactone, canrenone and
other steroids confirmed the results of Steimer et al. [15].
Spironolactone and canrenone, at concentrations esti-
mated to be the maximal blood concentrations found in
patients treated with these drugs, were shown to increase
the digoxin concentration by 4% and 15%, respectively.
Spironolactone metabolites at concentrations corre-
sponding to a daily intake of 100 mg falsely increased the
digoxin concentration by 7%.
It is important to note that the doses recommended for
patients with heart failure are considerably lower than this
(12.5–50 mg). The average intake in our study was 34 mg/
day. Furthermore, our results cannot be due to assay inter-
ference because the association between serum digoxin
concentrations and P-gp inhibitors remains statistically
significant even when all patients on spironolactone are
excluded from the study (1.46 ± 0.05 compared with 1.26
± 0.04 nmol/L, P < 0.001, for patients with and without
concomitant P-gp inhibitors, respectively).
Likely explanations for the more pronounced effect of
Class I P-gp inhibitors on S-digoxin levels compared with
Class II P-gp inhibitors are the inhibitory concentrations
for a certain drug in relation to the concentrations
achieved in clinical use. As the drugs have been evaluated
for P-gp inhibitory effect using several different in vitro
methods, it was not proper to perform a comparison of
the Ki or IC50 values from the literature. A majority of the
Class I inhibitors are given at higher doses than Class II
inhibitors (the range of the lowest recommended doses is
10–200 mg for Class I vs. 0.25–60 mg for Class II), and the
Class I inhibitors are often more potent, inhibiting dig-
oxin transport by P-gp in vitro at lower concentrations.
Other factors, such as time-point for the administration
and physiochemical properties of the drug, might also
contribute to the effect seen in vivo. Today, the in vitro data
used to select the Class II drugs is not sufficient for the pre-
diction of clinically relevant P-gp interactions in vivo.
Before such interactions are fully understood, the Class II
drugs should be regarded as potential mediators of drug-
drug interactions when coadministered with digoxin or
other P-gp substrates.
P-gp has a broad substrate specificity and, unfortunately,
it is not possible to state that a particular group of drugs,
for example, calcium channel blockers or HMG-coenzyme
The association between S-digoxin levels and the number of  prescribed Class I P-gp inhibitors Figure 2
The association between S-digoxin levels and the 
number of prescribed Class I P-gp inhibitors Adjusted* 
S-digoxin means for patients taking zero, one or two Class I 
P-gp inhibitors. The numbers of patients were 328, 96 and 
17, respectively. The S-digoxin means ± SE (nmol/L) were 
1.25 ± 0.04, 1.65 ± 0.07 and 1.83 ± 0.17. *Adjusted for age, 
sex, digoxin dose and total number of prescribed drugs.
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A inhibitors, are P-gp inhibitors with potential clinical
consequences. For instance, verapamil is a P-gp inhibitor
demonstrating clinical effects on digoxin kinetics,
whereas diltiazem is not [19]. Similarly, the HMG-coen-
zyme A inhibitor pravastatin is not an in vitro P-gp inhib-
itor [20], in contrast to atorvastatin, which is an in vitro P-
gp inhibitor that also demonstrates in vivo effects on P-gp
[11]. Any investigation of P-gp inhibitory effects and pos-
sible clinical consequences should, therefore, be made for
each single drug entity.
Conclusions
In this report we show that coadministration of P-gp
inhibitors with digoxin is associated with significant ele-
vations in S-digoxin levels in an ordinary group of digoxin
patients. To avoid exposing patients to excessive digoxin
levels, prescribing clinicians should consider potential P-
gp interactions. Particular notice should be taken when
more than one P-gp inhibitor is coadministered with dig-
oxin, as administration of more than one P-gp inhibitor is
associated with additive elevations in S-digoxin levels.
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